Effects of tislelizumab combined with platinum-containing dual-drug regimen in elderly patients with advanced lung adenocarcinoma

Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 1

Abstract

<b>Objective</b> To explore the efficacy of tislelizumab combined with pemetrexed and carboplatin chemotherapy in elderly patients with advanced lung adenocarcinoma and its effects on serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels. <b>Methods</b> Ninety-four driver gene-negative elderly patients with advanced lung adenocarcinoma admitted to the Fourth Affiliated Hospital of Nanjing Medical University from July 2021 to December 2022 were selected as the study subjects. They were divided into chemotherapy group (pemetrexed combined with carboplatin, n=48) and tislelizumab group (pemetrexed+carboplatin+tislelizumab, n=46) by the random number table method, and both groups were treated for 4 cycles, with 21 days as a cycle. The clinical efficacy, immune function [T lymphocyte subsets (CD4 <sup>+</sup>, CD8 <sup>+</sup>, CD4 <sup>+</sup>/CD8 <sup>+</sup>)] and serum indicators (IGF-1, IGFBP-3) before and after treatment were recorded in both groups, and the adverse reactions were assessed. <b>Results</b> The clinical efficacy and objective response rate (58.70% vs 29.17%, χ<sup>2</sup>=8.329, P<0.01) in tislelizumab group were significantly higher than those in chemotherapy group. After 4 cycles of treatment, the CD4 <sup>+</sup>, CD4 <sup>+</sup>/CD8 <sup>+</sup> and IGFBP-3 levels in both groups were significantly increased compared with those before treatment (P<0.05), and the indicators in tislelizumab group were higher than those in chemotherapy group (P<0.05); CD8 <sup>+</sup> and IGF-1 levels were significantly decreased in both groups compared with those before treatment (P<0.05), and the indicators in tislelizumab group were lower than those in chemotherapy group (P<0.05). Adverse reactions were mainly grade 1-2 in both groups, and there was no significant difference in the incidence of adverse reactions between two groups (P>0.05). <b>Conclusion</b> The first-line therapy of tislelizumab combined with platinum-containing dual-drug for elderly advanced lung adenocarcinoma can improve the clinical efficacy, improve the balance of CD4 <sup>+</sup>/CD8 <sup>+</sup>, regulate the expression of serum IGF-1 and IGFBP-3 levels. The adverse reactions are controllable, and the treatment regimen is safe and reliable.

Authors and Affiliations

WANG Fei*, LIU Pei, PU Jiaze, YU Jun

Keywords

Related Articles

Cognition and behavior of diabetic retinopathy in type 2 diabetes patients aged 50 and over in Funing County, Jiangsu Province

"<b>Objective</b> To investigate the cognition and behavior of diabetic retinopathy (DR) in patients with type 2 diabetes aged 50 and above in Funing County, Yancheng City, Jiangsu Province, and to evaluate its influenci...

Research progress of anesthesia management in cesarean section for maternal obesity

The incidence of obesity in pregnant women has been rapidly increasing worldwide, and the incidence and mortality of anesthesia-related complications during cesarean section surgery have been increased by pathophysiologi...

Epidemiological characteristics of notifiable infectious disease in Tongzhou District, Nantong from 2017 to 2022

Objective To analyze the epidemiological characteristics of notifiable infectious diseases in Tongzhou District of Nantong from 2017 to 2022, and provide scientific basis for developing targeted prevention and control st...

Animal experimental study of a new aortic arch fenestrated stent graft

Objective To evaluate the safety and efficacy of a novel aortic arch fenestrated membrane-covered stent graft implanted in situ in large animals after long-term maintenance. Methods Three healthy male Large White pigs (n...

Correlation between cardiometabolic index and stroke in middle-aged and older adults

Objective To explore the relationship between cardiac metabolic index (CMI) and stroke in middle-aged and elderly individuals based on a large sample cohort study. Methods Data were obtained from the China Health and Ret...

Download PDF file
  • EP ID EP735799
  • DOI 10.13429/j.cnki.cjcr.2024.01.007
  • Views 42
  • Downloads 0

How To Cite

WANG Fei<sup>*</sup>, LIU Pei, PU Jiaze, YU Jun (2024). Effects of tislelizumab combined with platinum-containing dual-drug regimen in elderly patients with advanced lung adenocarcinoma. Chinese Journal of Clinical Research, 37(1), -. https://europub.co.uk/articles/-A-735799